Cathay Biotech first-half net profit 372 million yuan, up 20.75% year on year

上海证券报··CN·Read original
3▲1 ▼0Impact / 5
Summary · why it matters

Cathay Biotech disclosed its 2026 semi-annual report. In the first half, it achieved operating revenue of 1.9 billion yuan, up 13.73% year on year, and net profit attributable to shareholders of the listed company of 372 million yuan, up 20.75% year on year. The profit growth was mainly driven by continued volume expansion of long-chain dibasic acids and revenue contribution from new product sales. During the reporting period, bio-based sebacic acid and bio-based piperidine continued to be introduced to the market, bio-based azelaic acid entered the customer sampling stage, and long-chain polyamide modified products achieved large-scale sales. The company also led an investment in and increased its stake in the AI protein design company MoleculeMind, and currently holds about 17.43% of its shares, making it the largest external shareholder. At the same time, its self-built high-throughput research and development platform has entered the commissioning stage.

Impact on assets 1

Others▲
Cathay Biotech Inc
688065
▲ PositiveCapitalrelevance

First-half net profit up 20.75% year on year, driven by volume expansion and new product sales.

Theme Impact 2

Off-coverage companies 1

北京分子之心科技有限公司i
Private± Mixedrelevance

Related news

Norway

Borregaard Refinances With NOK 1,500 Million Sustainability-Linked Credit Facilities

Borregaard has arranged new sustainability-linked multicurrency revolving credit facilities totaling NOK 1,500 million with three banks, replacing existing arrangements that were approaching maturity. The facilities secure continued access to committed funding, with loan terms tied to environmental and safety targets including greenhouse gas emission cuts and workplace safety measures. The company operates in the chemicals sector, focusing on specialized biochemicals and biomaterials for customers across Europe, Asia, the United States, and other regions. The refinancing keeps Borregaard's debt profile aligned with its buyback-and-earnings-reset narrative, tying borrowing costs to how effectively it runs its mills rather than to market rates alone. With profit margins recently weaker than a year ago, the flexible general-purpose credit leaves room to balance capacity upgrades against authorized share repurchases without overstretching the balance sheet.
About megatrends
Synthetic Biology (non-pharma) › Bio-Based Materials & Industrial Chemicals Capital
Critical Materials & Supply Chain › Specialty Chemicals & Industrial Gases Capital
0QB7.LSE · Capital · Positive Borregaard arranged NOK 1,500 million in new sustainability-linked revolving credit facilities, securing committed funding and refinancing maturing debt.
Read original ↗
Simply Wall St·2dRead more →
China
▼2

Xinxiang Chemical Fiber's 98.85 mu of industrial land to be reclaimed with compensation; some production lines to halt

Xinxiang Chemical Fiber announced at midday on October 9 that the right to use approximately 98.85 mu of transferred industrial land, located at the northwest corner of Muye Avenue and Genghuang Avenue, is to be reclaimed with compensation by the Fengquan District Government of Xinxiang City. The company plans to sign a compensation agreement with the Fengquan District Government of Xinxiang City, with the first-phase compensation for the land and above-ground attachments totaling 51.2334 million yuan. Subsequent agreements will be signed separately based on demolition progress, asset disposal, and acceptance inspection. In view of the change in the aforementioned land use right, the company has decided to halt production at its northern district bio-based cellulose filament production line and its subsidiary Xinglu Technology starting from October 12. This is expected to reduce the company's operating revenue by approximately 260 million yuan and reduce total profit by approximately 40 million yuan. Apart from the production lines halted this time, the company's other major production facilities will continue normal operations.
About megatrends
Synthetic Biology (non-pharma) › Bio-Based Materials & Industrial Chemicals ▼Supply
000949.CS · Regulation · Negative Government reclamation of its industrial land forces halt of bio-based cellulose filament and Xinglu Technology lines, cutting revenue ~260M yuan and profit ~40M yuan.
Read original ↗
证券时报·2dRead more →
GermanyUnited States
▲

Verbio Opens Ethenolysis Plant, Shifts Focus to Capacity Utilization

Verbio SE outlined its next development phase at its Capital Markets Day in Bitterfeld, marking the commissioning of a new ethenolysis plant for bio-based speciality chemicals as a milestone in the expansion of its renewable-molecule production platform and biorefineries. After years of high investment, the company said its focus is now increasingly on utilizing the capacity it has created, optimizing existing production plants and increasing earnings and cash flow. The event covered the market and competitive positioning of Verbio's existing business divisions, the further development of its business base in the USA, and the commercial ramp-up of its new chemical products. Verbio pointed to the resurgence of biomass as a raw material revitalizing the biofuels market while opening new value-creation opportunities beyond it, including expanded trading activities and additional revenue potential from the utilization and storage of biogenic CO2. Chief Executive Officer Claus Sauter said Verbio has developed over two decades from a biofuel producer into an integrated platform for a wide range of renewable molecules, with the company's twentieth flotation anniversary days away, and that it will now harness that platform's potential to generate value, cash flow and long-term returns for shareholders. Verbio also reaffirmed its commitment to disciplined capital use and a balanced approach between profitable growth, financial stability and sustainable value creation.
About megatrends
Synthetic Biology (non-pharma) › Bio-Based Materials & Industrial Chemicals ▲Supply
Synthetic Biology (non-pharma) › Sustainable Aviation Fuel & Bio-Fuels ▲Supply
VBK.XETRA · Technology · Positive Commissioning of new ethenolysis plant expands Verbio's renewable-molecule platform and opens new chemical product value-creation.
Read original ↗
NEWMEDIAWIRE·2dRead more →
United StatesVietnam
▲

Kraig Biocraft Ships First Commercial Spider Silk Yarn to Sports Brand

Kraig Biocraft Laboratories announced on September 29 that its first commercial order of recombinant spider silk yarn had shipped to a globally recognized performance sports brand, processed to the customer's specifications for a confidential pilot development program. The company's engineered silkworms, Bombyx mori, carry introduced spider-silk protein genes and spin the resulting composite fiber as they form cocoons. In its October 5 update, Kraig reported that all three of its production centers in Vietnam were running on staggered schedules, with the current cycle focused on parental breeding lines that supply hybrid eggs for subsequent silk production, and that silk production grew more than 30% through the rainy season. On September 24, 2026, the company announced that every planned Project Atlas transgene had been integrated into living commercial silkworm hosts, with the next stage establishing stable breeding lines and evaluating more than 200 potential genetic pairing configurations. Kraig's founder and CEO, Kim Thompson, said the company is no longer producing to demonstrate and confirm scale, and that production is now focused on addressing the commercial market opportunities for spider silk.
About megatrends
Synthetic Biology (non-pharma) › Bio-Based Materials & Industrial Chemicals ▲Supply
Read original ↗
Wall Street PR·4dRead more →
United StatesBrazilMexicoSouth Korea

CJ CheilJedang and ADM to Form Amino Acid Joint Venture Majority Owned by CJ

CJ CheilJedang and ADM have agreed to form a new joint venture to secure a reliable, long-term source of feed-grade amino acids critical to the livestock industry, strengthening U.S. production, global supply chain resilience and U.S. food security. The joint venture will develop, manufacture and market fermentation-derived amino acids by combining CJ's fermentation production facilities in Fort Dodge, Iowa, and Piracicaba, Brazil, ADM's Decatur, Illinois, feed-grade amino acid plant, and CJ's Mexico, Brazil and U.S. sales offices, along with a license to CJ's intellectual property related to feed-grade amino acids for use by the joint venture within North and South America. CJ and ADM will give the JV exclusive rights to manufacture and sell feed-grade amino acids in the Americas, and CJ will be the majority owner. CJ will retain ownership of its intellectual property and its global fermentation businesses outside the scope of the joint venture, while ADM's other Decatur operations and its other global fermentation assets are not included in the transaction. The launch date for the proposed joint venture is subject to customary closing activities as well as regulatory approvals.
About megatrends
Synthetic Biology (non-pharma) › Bio-Based Materials & Industrial Chemicals Supply
097950.KO · Capital · Positive CJ CheilJedang will be majority owner of the new amino acid JV, contributing its Fort Dodge and Piracicaba plants and licensing its IP.
ADM · Capital · Positive ADM contributes its Decatur feed-grade amino acid plant to a new JV with CJ, expanding its fermentation footprint and securing long-term amino acid supply.
Read original ↗
ThailandHong Kong SAR ChinaUnited States
6

BCP Jumps 5% as Broker Highlights SAF Project, Sees Q3 EBITDA Topping 2 Billion Baht, Buy Rating with 56 Baht Target

Shares of Bangchak Corporation Public Company Limited, or BCP, rose 5.05% to 52.00 baht at 10:05 a.m. on October 2, 2026, on trading value of 300.57 million baht, after Land and Houses Securities said in an analysis that the company's sustainable aviation fuel, or SAF, project of BSGF Company Limited, in which BCP holds an 80% stake, is Thailand's first stand-alone SAF production project. Located at the Bangchak Phra Khanong refinery, it uses mainly used cooking oil as feedstock and Hydroprocessed Esters and Fatty Acid technology to produce neat SAF, as well as Bio-LPG and Bionaphtha, with initial production capacity of about 1 million liters per day. The project was completed with an investment of about 8.5 billion baht, first produced in May 2026, and in the second quarter of 2026 ran at an average of about 6,800 barrels per day, or roughly 1.08 million liters per day, with total sales of about 39 million liters and EBITDA of about 1 billion baht, even though commercial operations began only halfway through the quarter. It received an eight-year corporate income tax exemption and a 50% tax reduction for the following five years from the Board of Investment. Land and Houses Securities expects the SAF business to begin generating full-quarter profits for the first time in the third quarter of 2026 and sees a chance of EBITDA exceeding 2 billion baht in that quarter, potentially reaching about 8 billion baht on a full-year basis in 2027. Meanwhile, the acquisition of Chevron Hong Kong, completed at the end of the second quarter of 2026, will also begin contributing a full quarter of results for the first time in the third quarter of 2026. It therefore maintained a buy rating on BCP with a target price of 56 baht. Trinity Securities said after visiting the project that the plant runs at an average utilization rate of about 6,800 barrels per day, close to its designed capacity of 7,000 barrels per day, and has the flexibility to switch between SAF and HVO, or renewable diesel, with SAF yields of about 90% while HVO is about 98%. It also views the project as adding about 7,000 barrels per day of new production capacity to BCP's portfolio, on top of its existing refining base of about 294,000 barrels per day, with plans to raise capacity by about 50% from roughly 1 million liters per day to 1.5 million liters per day, equivalent to about 10,000 to 11,000 barrels per day. It recommended buying BCP with a target price of 55 baht.
About megatrends
Synthetic Biology (non-pharma) › Sustainable Aviation Fuel & Bio-Fuels ▲Supply
Synthetic Biology (non-pharma) › Bio-Based Materials & Industrial Chemicals Supply
BCP.BK · Capital · Positive Land and Houses Securities maintains buy rating with 56 baht target, citing SAF project and Q3 EBITDA potentially exceeding 2 billion baht.
BSGF Co., Ltd. · Capital · Positive BSGF's SAF project is highlighted as Thailand's first stand-alone SAF production, with expected full-quarter profits and EBITDA exceeding 2 billion baht in Q3 2026.
Read original ↗
Kaohoon·9dRead more →